BeiGene, Ltd. (ONC)vsUroGen Pharma Ltd (URGN)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
URGN
UroGen Pharma Ltd
$18.12
+2.60%
HEALTHCARE · Cap: $882.12M
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 4767% more annual revenue ($5.34B vs $109.79M). ONC leads profitability with a 5.4% profit margin vs -139.8%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
URGN
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for URGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Revenue surging 54.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1481.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : URGN
The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 54.0% demonstrates continued momentum.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : URGN
The primary concerns for URGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
URGN carries more volatility with a beta of 1.37 — expect wider price swings.
URGN is growing revenue faster at 54.0% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 28/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →UroGen Pharma Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
UroGen Pharma Ltd (URGN) is a biotechnology company focused on pioneering therapies for urological conditions, particularly urothelial carcinoma and bladder cancer. Utilizing its proprietary reverse thermal gel platform, UroGen facilitates sustained local drug delivery, enhancing therapeutic effectiveness while minimizing systemic exposure. The company boasts a robust clinical pipeline aimed at addressing critical unmet needs within urology, positioning itself as a leader in the sector with the potential to significantly improve patient outcomes.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?